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OBJECTIVES: TNF-inhibitors were the first biological therapies approved for RA
treatment and five are approved by the US FDA: etanercept (ETN), adalimumab
(ADA), infliximab (IFX), certolizumab pegol (CZP) and golimumab (GOL). The study
objective was to understand “real-life” dosing patterns, including dose-escalation,
whichmay impact costs/outcomes of TNF-inhibitor therapy.METHODS:Weused a
longitudinal claims database (i3 Pharma Informatics) to assess RA patients receiv-
ing ETN, ADA, or IFX. Due to product launch date, CZP and GOL were excluded.
Patients having a TNF-inhibitor claim, RAdiagnosis (ICD-9: 714.0), at least 6months
pre-biologic eligibility and 24-months enrollment post-claim from January 2007–
March 2009were included. Dose-escalationwas defined as an increase in bi-weekly
dosing from 40 to 80mg for ADA, an increase in weekly dosing from 25 to 50/100mg
or 50 to 100mg for ETN, and the addition of 1 vial to the subsequent 8-weekly
maintenance treatment dose, or a reduction in weeks between IFX treatments.
RESULTS: A total of 59,928 patients filled a TNF-inhibitor prescription and 3448
were eligible for inclusion in this analysis. Dose-escalation rates were 13% for ADA,
3% for ETN, and 39% for IFX. Additionally, 6% of patients initiated on 25mg ETN
experienced dose-escalation versus baseline. Switching to another biologic oc-
curred in 14% (ETN), 16% (ADA) and 17% (IFX).CONCLUSIONS:These “real-life” data
confirm dose-escalation occurs in clinical practice. Further analyses including all
anti-TNF approvals should be performed to further elucidate the clinical and cost
implications for physicians and payers. A limitation of this study is lack of stan-
dardized methodology for calculating anti-TNF doses from claims data. Previous
studies report a range of dose-escalation rates for ETN (1-17%), ADA (0-12%), and
IFX (30-53%). In this study, cut-points were based on current standards of care
correlated with frequency distributions within a closed system, ensuring resulting
dose-escalation rates are clinically representative.
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OBJECTIVES: Fibromyalgia (FM) is a chronic condition characterized bywidespread
pain and can impose substantial economic burden. This study estimates the an-
nualized differences in healthcare costs associated with improvement in FM se-
verity among pregabalin-treated patients. METHODS: Data from 3 similarly de-
signed, 3-month placebo-controlled, clinical trials of pregabalin in FM patients
were modeled. Extrapolation of efficacy results was based on a 1-year open-label
study. Mean annual costs (direct and indirect) were assigned based on FM severity
levels (mild: $10,219;moderate: $26,217; severe: $42,456) andwere derived from the
US Fibromyalgia Burden of Illness Study. FM severity levels were defined using
established cutpoints on the Fibromyalgia Impact Questionnaire. Mean annualized
costs at endpoint were estimated for all patients within each cohort and the mean
differences in costs were compared between cohorts using a regression model.
RESULTS: Relative to placebo, the proportion of mild subjects at endpoint was
significantly higher with pregabalin 450mg and significantly lower for severe sub-
jects. Mean total costs were lowerwith pregabalin (300mg, $25,721; 450mg, $24,103)
thanplacebo ($26,162). Relative to placebo, the difference inmean annual costswas
$2059 lower for pregabalin 450mg (P0.003) and $441 lower for pregabalin 300mg
(P0.52). Mean direct costs were higher with pregabalin (300mg, $4,962; 450mg,
$4820) than placebo ($4,364). Relative to placebo, the difference in mean annual
direct costs was significantly higher for pregabalin 450mg by $456 (P0.0001) and
by $599 for pregabalin 300mg (P0.0001). Mean indirect costs for pregabalin
(300mg, $20,783; 450mg, $19,306) were lower than placebo ($21,735). Relative to
placebo, the difference in mean annual direct costs for pregabalin 450mg was
significantly lower by $2,429 (P0.0001), and for pregabalin 300mg was lower by
$951 (P0.12). CONCLUSIONS: Improvements in FM severity are associated with
overall reductions in costs that may offset the costs of treatment with pregabalin.
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OBJECTIVES: While the etiology of fibromyalgia syndrome (FMS) is unknown, the
incidence of FMS has been on the rise over the years. There is no known cure or
universally accepted treatment for FMS and the treatment is typically aimed at
symptom management. Although patients with FMS are known to have higher
pharmacy-related costs compared to those without FMS due to high usage of pain-
relieving medications, the true financial burden on newly diagnosed FMS patients
remains unclear. The purpose of this study was to compare health care utilization
and patient financial burden of FMS patients at pre- and post-diagnosis.
METHODS: Nationwide commercial claims database which includes EPO, PPO,
HMO and POS managed care systems was used to identify 194 patients who were
newly diagnosed with FMS in year 2008 (identified by ICD-9-CM of 729.10). Patients
with chronic comorbidities including other musculoskeletal diseases, cancer, HIV/
AIDS, or asthma/COPD were excluded from the study. Health care utilization (de-
fined by number of outpatient medical services) and patient financial burden (de-
fined by out-of-pocket [OOP] costs including co-pay, deductible, and coinsurance)
were assessed for two time intervals – sixmonths prior to and after the diagnosis of
FMS. RESULTS: Mean age of newly diagnosed FMS patients was 44 years (SD14)
and 143 of 194 patients were females. The majority of patients (74%) were enrolled
in point of service managed care systems. FMS patients had higher health care
utilization post-diagnosis when compared to pre-diagnosis but the results were
not statistically significant (28 vs. 26, respectively; p0.35). OOP costs remained
relatively unchanged for the two time periods (p0.59). CONCLUSIONS: Patients
newly diagnosed with FMS use only slightly higher health care utilization upon
diagnosis of FMS when compared with pre-diagnosis period while studies involv-
ing pharmacy utilization indicate significantly higher utilization.
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OBJECTIVES: Assess the impact of disease remission, a treatment target in the
management of rheumatoid arthritis (RA) recommended by the International Task
Force, on patient-reported outcomes (PROs).METHODS:Golimumab (GLM) efficacy
and safety were assessed in methotrexate (MTX)-naïve RA patients (GO-BEFORE,
N637), RA patients with inadequate MTX response (GO-FORWARD, N444) and
anti-TNFa-experienced patients with baseline MTX use (GO-AFTER, N305). Pa-
tients received placeboMTX, or GLM (50 or 100mg)MTX q4wks. Clinical remis-
sionwas defined as a 28-joint DiseaseActivity Score (DAS28)2.6. PRO assessments
included Health Assessment Questionnaire (HAQ), 36-item short-form health sur-
vey (SF-36) physical/mental component summary (PCS/MCS) scores, Assessment
of Chronic Illness Therapy-Fatigue (FACIT-F), Pain Severity Score of Brief Pain In-
ventory (BPI-Pain) and a visual analog scale of daily work productivity An ANOVA
on van derWaerden normal scores or Chi-square test was performed for between-
group comparisons. RESULTS: At wk24, greater proportions of GLMMTX-treated
patients achievedDAS28 remission versus PBOMTX (GO-BEFORE: 22.3% vs. 11.3%,
GO-FORWARD: 21.4% vs. 6.0%, GO-AFTER: 14.8% vs. 2.0%; all p0.01). GLMMTX-
treated patients had greater PRO improvement versus PBOMTX. From wk24-104,
the overall SF-36 PCS score distribution shifted significantly towards the normal
distribution.More patients in remission thannot atwk24 achievedHAQ0.5 (72.2%
vs. 24.3%), SF-36 PCS50 (general population median) (48.3% vs. 7.6%) and SF-36
MCS50 (66.3% vs. 40.3%), regained employability (39.6% vs. 24.1%) and signifi-
cantly improved work productivity (80.1% vs. 25.6%) from baseline (all p0.01).
Greater median improvements in FACIT-Fatigue (wk24: 12.0 vs. 5.0) and BPI-Pain
(wk14: 2.1 vs. 0.8) scoreswere observed among patients in, versus not in, remission.
After achieving remission, MTX-naïve RA patients (GO-BEFORE) had greater im-
provements in PROs than MTX-inadequate responders (GO-FORWARD) or anti-
TNF-experienced patients (GO-AFTER). CONCLUSIONS: Analysis results indicate
controlling RA activity is crucial to regaining a normal life, and treating-to-target
earlier (e.g., DAS28 remission) leads to better patient outcomes.
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OBJECTIVES: To assess the association of disease flares with clinical outcomes,
health status, andwork productivity loss among patientswith RA.METHODS:Data
were collected from individuals aged18 and reporting an RA diagnosis through a
cross-sectional, self-administered, Internet-based questionnaire. Frequency of
disease flares were categorized as: no flares (reference group),1 per month, 1 per
month, 2-3 per month, 1 per week, 2-3 per week, 4-6 per week, and daily. Clinical
outcomes included the Health Assessment Questionnaire (HAQ) and severity of
morning stiffness, fatigue, and pain, measured as 1none experienced to 10se-
vere. Health status was assessed using the SF-36, and work productivity loss (em-
ployed individuals only) and activity impairment were assessed using the Work
Productivity and Activity Impairment questionnaire. Patient demographics and
comorbidities were adjusted using linear regression and negative binomial regres-
sion as appropriate. RESULTS: Of 2,135 patients, 47.4% (n1,011) experienced a
disease flare in the past six months and 52.7% (n1,124) experienced no flares.
Greater frequency of flares was significantly associated with greater functional
disability; greater severity of morning stiffness, fatigue, and pain; poorer physical
and mental health status; greater lost work productivity and activity impairment.
Specifically, daily flares were associated with greater functional disability (HAQ:
regression coefficient b0.56, p0.001); greater severity of morning stiffness
(b2.27, p0.001), fatigue (b2.20, p0.001), and pain (b2.51, p0.001); poorer
health status (SF-36 physical component summary: b-8.76, p0.001 and mental
component summary: b-7.48, p0.005); and greater work impairment (event ra-
tio2.20, p0.001) and activity impairment (event ratio1.68, p0.001).
CONCLUSIONS: RA disease flares are associated with worse clinical outcomes,
poorer health status, and greater lost work productivity. However, due to the cross-
sectional nature of the study, the direction of these associations cannot be deter-
mined. Treatments that minimize disease flares may provide additional benefit in
clinical outcomes, health status, and work productivity.
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